Real-world data analysis of efficacy and survival after Lu-177 PSMA
177Lu-PSMA radioligand therapy provides a significant response rate with a [...]
PSMA Lu-177 x Ac-225
Available since 2015, the treatment of patients with metastatic castration-resistant [...]
What is in the pipeline for nuclear medicine, globally?
In recent years, the nuclear medicine market has undergone many [...]
Oncidium foundation welcomes it’s Turkish Ambassador
Welcome Mr. Hasan Ulaş Özcan as an Oncidium foundation Ambassador [...]
Oncidium foundation is a corporate member of the SNMMI Value Initiative
The Oncidium foundation is a corporate member of the Society [...]
Joint Radionuclide Therapy-Immunotherapy Approach Effective in Prostate Cancer Model
Joint radionuclide therapy and immunotherapy approach. The combination shows promising [...]
October Rose – Breast Cancer Awareness Month
The Oncidium foundation wears the colors of October Rose. Breast [...]
Nuclear Medicine and Molecular Imaging Week: October 4-10, 2020
October 4-10 2020 is nuclear medicine and molecular imaging week! [...]
First clinical results for PSMA TAT using Ac-225-PSMA-I&T in advanced mCRPC patients
First clinical results for PSMA targeted alpha therapy using 225Ac-PSMA-I&T [...]
IAEA activities on Cu-67, Re-186, Sc-47 Theranostic radionuclides and Radiopharmaceuticals
International Atomic Energy Agency (IAEA) activities on 67Cu, 186Re, 47Sc [...]